Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIPNASDAQ:DYNNASDAQ:HRTXNASDAQ:INDV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$68.70+2.3%$60.09$52.50▼$70.05$1.50B0.63260,718 shs190,181 shsDYNDyne Therapeutics$11.57+2.7%$13.38$10.72▼$47.45$1.32B1.112.12 million shs466,242 shsHRTXHeron Therapeutics$2.34+2.0%$1.97$1.04▼$3.93$355.69M1.552.34 million shs433,589 shsINDVIndivior$9.84+1.5%$10.32$7.33▼$22.53$1.36B0.82632,861 shs592,433 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+1.27%+3.55%+20.87%+21.03%-3.42%DYNDyne Therapeutics-1.23%-9.19%-17.14%-53.98%-57.95%HRTXHeron Therapeutics-2.55%-6.53%+29.38%+43.13%-16.42%INDVIndivior+1.15%-2.61%+17.45%-21.35%-52.89%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals3.8412 of 5 stars2.51.00.03.33.43.31.3DYNDyne Therapeutics3.2145 of 5 stars4.51.00.00.02.34.20.0HRTXHeron Therapeutics3.9867 of 5 stars3.50.00.04.24.31.70.6INDVIndivior3.4412 of 5 stars3.63.00.00.02.71.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$79.7516.09% UpsideDYNDyne Therapeutics 3.07Buy$47.46310.25% UpsideHRTXHeron Therapeutics 3.00Buy$5.67142.68% UpsideINDVIndivior 3.25Buy$15.0052.49% UpsideCurrent Analyst Ratings BreakdownLatest HRTX, ANIP, DYN, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025DYNDyne TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $17.003/17/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$94.00 ➝ $94.003/17/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.003/17/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.003/14/2025ANIPANI PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.003/12/2025ANIPANI PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$85.003/12/2025DYNDyne TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$50.003/7/2025DYNDyne TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$50.003/6/2025INDVIndiviorPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $13.003/5/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$84.00 ➝ $86.003/3/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$94.00 ➝ $94.00(Data available from 3/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M2.43$7.61 per share9.03$21.13 per share3.25DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/AHRTXHeron Therapeutics$144.29M2.47N/AN/A($0.23) per share-10.15INDVIndivior$1.19B1.14$1.99 per share4.94N/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals$18.78M-$1.14N/A16.32N/A-1.28%15.87%6.88%5/9/2025 (Estimated)DYNDyne Therapeutics-$235.94M-$3.35N/AN/AN/AN/A-57.46%-51.62%5/1/2025 (Estimated)HRTXHeron Therapeutics-$110.56M-$0.09N/AN/AN/A-20.31%N/A-12.72%5/6/2025 (Estimated)INDVIndivior$2M-$0.35N/A5.75N/A-3.96%-241.73%15.09%4/24/2025 (Estimated)Latest HRTX, ANIP, DYN, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/24/2025N/AINDVIndivior$0.22N/AN/AN/A$240.13 millionN/A3/4/2025Q4 2024DYNDyne Therapeutics-$0.92-$0.88+$0.04-$0.88N/AN/A2/27/2025Q4 2024HRTXHeron Therapeutics-$0.03$0.02+$0.05$0.02$37.37 million$40.78 million2/20/2025Q4 2024INDVIndivior$0.32$0.32N/A$0.07$262.35 million$298.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.522.741.97DYNDyne TherapeuticsN/A17.0217.02HRTXHeron TherapeuticsN/A2.281.74INDVIndiviorN/A0.830.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%DYNDyne Therapeutics96.68%HRTXHeron Therapeutics80.01%INDVIndivior60.33%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals12.70%DYNDyne Therapeutics20.77%HRTXHeron Therapeutics5.76%INDVIndiviorN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.77 million18.36 millionOptionableDYNDyne Therapeutics100113.12 million80.63 millionOptionableHRTXHeron Therapeutics300152.33 million143.33 millionOptionableINDVIndivior1,164137.88 millionN/ANot OptionableHRTX, ANIP, DYN, and INDV HeadlinesRecent News About These Companies133,183 Shares in Indivior PLC (NASDAQ:INDV) Purchased by Kazazian Asset Management LLCMarch 20, 2025 | marketbeat.comIndivior PLC (NASDAQ:INDV) Sees Significant Increase in Short InterestMarch 16, 2025 | marketbeat.comIndivior (NASDAQ:INDV) Shares Gap Down - What's Next?March 12, 2025 | marketbeat.comIndivior (NASDAQ:INDV) Given New $13.00 Price Target at Piper SandlerMarch 7, 2025 | marketbeat.comShort Interest in Indivior PLC (NASDAQ:INDV) Drops By 14.1%March 5, 2025 | marketbeat.comIndivior (NASDAQ:INDV) Trading 6.3% Higher - Time to Buy?March 4, 2025 | marketbeat.comIndivior Announces Further Changes to Board of DirectorsMarch 4, 2025 | prnewswire.comPromising Cannabis Stocks To Watch Today - March 3rdMarch 3, 2025 | marketbeat.comIs Indivior PLC (INDV) the Best Small Cap Pharma Stock to Buy Now?March 2, 2025 | msn.comVELA Investment Management LLC Has $2.26 Million Stock Position in Indivior PLC (NASDAQ:INDV)March 1, 2025 | marketbeat.comIndivior (NASDAQ:INDV) Sees Large Volume Increase - Here's What HappenedFebruary 28, 2025 | marketbeat.comUK's Indivior appoints Joe Ciaffoni as CEOFebruary 27, 2025 | reuters.comIndivior Announces Joseph Ciaffoni Appointed Chief Executive OfficerFebruary 27, 2025 | prnewswire.comIndivior price target lowered to $15 from $16 at Craig-HallumFebruary 21, 2025 | markets.businessinsider.comIndivior targets $1.5B peak revenue for Sublocade amid 2025 transition plansFebruary 20, 2025 | seekingalpha.comIndivior price target lowered to 1,100 GBp from 1,400 GBp at StifelFebruary 20, 2025 | markets.businessinsider.comIndivior PLC 2024 Q4 - Results - Earnings Call PresentationFebruary 20, 2025 | seekingalpha.comIndivior PLC (INDV) Q4 Earnings Meet EstimatesFebruary 20, 2025 | zacks.comIndivior drops 23% after sounding the alarm over 2025 performanceFebruary 20, 2025 | proactiveinvestors.co.ukIndivior weakness on delay a buying opportunity, says NorthlandFebruary 13, 2025 | markets.businessinsider.comCraig-Hallum Sticks to Its Buy Rating for Indivior (INDV)February 12, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy 3 Companies Buying Back Stock—Why It MattersBy Gabriel Osorio-Mazilli | March 12, 2025View 3 Companies Buying Back Stock—Why It MattersChaos and Cash: Finding Opportunity in VolatilityBy Jeffrey Neal Johnson | March 2, 2025View Chaos and Cash: Finding Opportunity in Volatility3 Stocks Breaking Out with More Growth Potential AheadBy Gabriel Osorio-Mazilli | February 28, 2025View 3 Stocks Breaking Out with More Growth Potential AheadHRTX, ANIP, DYN, and INDV Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$68.69 +1.53 (+2.27%) As of 02:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Dyne Therapeutics NASDAQ:DYN$11.57 +0.31 (+2.74%) As of 02:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Heron Therapeutics NASDAQ:HRTX$2.34 +0.05 (+1.97%) As of 02:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Indivior NASDAQ:INDV$9.84 +0.15 (+1.52%) As of 02:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Maybe It’s Time to Buy Some GameStop Stock Intel's Strategy to Win the Next AI Frontier Is Alphabet Too Cheap to Ignore After Its Recent Correction? Qualcomm Stock Is Coiling for a Breakout Tesla Stock: Has the Mother of All Comebacks Begun? Fortinet: A Top Cybersecurity Stock With Growth Catalysts Energy Transfer: Powering Data With Dividends and Diversification Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
